• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NOX
Click for more information
4.76% 10.0¢

NOXOPHARM LIMITED - Announcements

Market Cap $29.22M  ! watchlist Created with Sketch. Add to my watchlist

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel... Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
NOX Appendix 3B25/03/19
NOX Section 708 Certificate25/03/19
NOX Becoming a substantial holder21/03/19
NOX KZA: Kazia sells stake in NoxopharmPRICE SENSITIVE19/03/19
NOX NOX provides update to Nyrada Note Holders06/03/19
NOX New Corporate Presentation Released05/03/19
NOX Noxopharm to expedite Veyonda Clinical ProgramPRICE SENSITIVE21/02/19
NOX Appendix 4D and Half Year AccountsPRICE SENSITIVE21/02/19
NOX Change of Director's Interest Notice - GK14/02/19
NOX Updated Share Trading Policy08/02/19
NOX FNN interview with Nox Chief Medical Officer on Interim DataPRICE SENSITIVE06/02/19
NOX Veyonda and Radiotherapy Delivers Clinical BenefitsPRICE SENSITIVE06/02/19
NOX Appendix 3B01/02/19
NOX Appendix 4C - QuarterlyPRICE SENSITIVE29/01/19
NOX Principal Investigator Discusses LuPIN-1 StudyPRICE SENSITIVE14/01/19
NOX Change of Director's Interest Notice - GK21/12/18
NOX Section 708 Certificate21/12/18
NOX Appendix 3B21/12/18
NOX NOX Receives $3.26M Federal Govt R&D RebatePRICE SENSITIVE20/12/18
NOX DARRT-1 study advancing on basis of positive clinical dataPRICE SENSITIVE11/12/18
NOX NOX announces Positive Data from CEP-1 Study of VeyondaPRICE SENSITIVE29/11/18
NOX Initial Director's Interest Notice21/11/18
NOX Results of Meeting21/11/18
NOX Appointment of Mr John Moore as Non-Executive Director21/11/18
NOX NOX 2018 AGM Presentations21/11/18
NOX NOX 2018 AGM Information20/11/18
NOX NOX to Present Clinical Data at COSA Annual MeetingPRICE SENSITIVE13/11/18
NOX Corporate Presentation08/11/18
NOX Appendix 4C - quarterlyPRICE SENSITIVE26/10/18
NOX NOX makes key executive appointment22/10/18
NOX Notice of Annual General Meeting & Proxy Form05/10/18
NOX Noxopharm Releases Report on Key Progress of Subsidiary04/10/18
NOX Section 708 Certificate02/10/18
NOX Appendix 3B02/10/18
NOX Change of Director's Interest Notice - PM28/09/18
NOX Section 708 Certificate28/09/18
NOX Appendix 3B28/09/18
NOX Change of Registry Address: Automic P/L - Sydney Office28/09/18
NOX Annual Report to shareholders27/09/18
NOX Corporate Governance Statement - Appendix 4G27/09/18
NOX Corporate Governance Statement - 201827/09/18
NOX NOX Subsidiary Announces Important Drug DiscoveryPRICE SENSITIVE24/09/18
NOX NOX to support expanded LuPIN studyPRICE SENSITIVE05/09/18
NOX Appendix 4E and Audited Financial StatementsPRICE SENSITIVE30/08/18
NOX Nyrada-Key progress with cholesterol-lowering drug candidatePRICE SENSITIVE27/08/18
NOX VEYONDA - Registered Trade Mark for NOX66PRICE SENSITIVE20/08/18
NOX NOX Corporate Presentation FNN-Shaw&Partners Investor Event14/08/18
NOX Change of Director's Interest Notice - GK09/08/18
NOX Change of Director's Interest Notice - PM09/08/18
NOX Change of Director's Interest Notice - ID09/08/18
NOX Appendix 3B09/08/18
NOX Interim NOX66 Radiotherapy Clinical Data08/08/18
NOX Appendix 4C - quarterlyPRICE SENSITIVE30/07/18
NOX Securities to be released from Escrow10/07/18 download Created with Sketch. 77.33KB
NOX Release of DARRT-1 Preliminary Safety DataPRICE SENSITIVE09/07/18 download Created with Sketch. 239.09KB
NOX Pre-Clinical data confirms Radio-Enhancing potentialPRICE SENSITIVE05/07/18 download Created with Sketch. 169.52KB
NOX Noxopharm releases Nyrada Corporate Presentation07/06/18 download Created with Sketch. 1.54MB
NOX Noxopharm Corporate Presentation for Public Briefing07/06/18 download Created with Sketch. 13.14MB
NOX End-of-Study Clinical Data shows benefit of NOX66PRICE SENSITIVE05/06/18 download Created with Sketch. 264.42KB
NOX Noxopharm 2018 Mid-Year Investor Briefings31/05/18 download Created with Sketch. 150.63KB
NOX Section 708 Certificate28/05/18 download Created with Sketch. 233.72KB
NOX Appendix 3B28/05/18 download Created with Sketch. 564.14KB
NOX NOX to present at American Society of Clinical OncologyPRICE SENSITIVE22/05/18 download Created with Sketch. 257.98KB
NOX KZA: Progress Report21/05/18
NOX Change in substantial holding21/05/18
NOX Securities to be released from Voluntary Escrow21/05/18
NOX Section 708 Certificate21/05/18
NOX Appendix 3B21/05/18
NOX Noxopharm 2018 Mid-Year Investor Briefings18/05/18
NOX Results of Meeting15/05/18
NOX NOX CEO interview updates the company's current R&D program07/05/18
NOX NOX CEO interview on near complete NOX66 chemotherapy trialPRICE SENSITIVE03/05/18
NOX NOX CEO interview on Radiotherapy Clinical ProgramsPRICE SENSITIVE27/04/18
NOX Appendix 4C - quarterlyPRICE SENSITIVE27/04/18
NOX St Vincent's Hospital study passes first milestonePRICE SENSITIVE17/04/18
NOX Notice of Extraordinary General Meeting / Proxy Form09/04/18
NOX Change in substantial holding06/04/18
NOX Change in substantial holding06/04/18
NOX DARRT-1 Clinical Study commencesPRICE SENSITIVE05/04/18
NOX NOX Mid-Year Briefings05/04/18
NOX Section 708 Certificate29/03/18
NOX Appendix 3B29/03/18
NOX NOX raises $10.8 M to advance clinical programPRICE SENSITIVE23/03/18
NOX Trading HaltPRICE SENSITIVE21/03/18
NOX Evidence of Abscopal Responses in PatientsPRICE SENSITIVE21/03/18
NOX Corporate Presentation - Post Interim Clinical Data Release12/03/18
NOX FNN Interview with Noxopharm CEO09/03/18
NOX NOX Reports NOX66 Clinical DataPRICE SENSITIVE06/03/18
NOX Trading HaltPRICE SENSITIVE05/03/18
NOX Update accompanying Half Year Report23/02/18
NOX Appendix 4D and Half Year AccountsPRICE SENSITIVE23/02/18
NOX NOX closes $4m capital raising for US subsidiary Nyrada IncPRICE SENSITIVE16/02/18
NOX Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
NOX Section 708 Certificate25/01/18
NOX Appendix 3B25/01/18
NOX KZA: Receipt of securities in Noxopharm Limited (NOX)22/01/18
NOX Section 708 Certificate18/01/18
NOX Appendix 3B18/01/18
NOX NOX receives FY17 R&D Tax RebatePRICE SENSITIVE17/01/18
NOX Kazia Therapeutics Ltd and Noxopharm Ltd27/12/17
NOX Appendix 3B
25/03/19
NOX Section 708 Certificate
25/03/19
NOX Becoming a substantial holder
21/03/19
NOX KZA: Kazia sells stake in Noxopharm
19/03/19PRICE SENSITIVE
NOX NOX provides update to Nyrada Note Holders
06/03/19
NOX New Corporate Presentation Released
05/03/19
NOX Noxopharm to expedite Veyonda Clinical Program
21/02/19PRICE SENSITIVE
NOX Appendix 4D and Half Year Accounts
21/02/19PRICE SENSITIVE
NOX Change of Director's Interest Notice - GK
14/02/19
NOX Updated Share Trading Policy
08/02/19
NOX FNN interview with Nox Chief Medical Officer on Interim Data
06/02/19PRICE SENSITIVE
NOX Veyonda and Radiotherapy Delivers Clinical Benefits
06/02/19PRICE SENSITIVE
NOX Appendix 3B
01/02/19
NOX Appendix 4C - Quarterly
29/01/19PRICE SENSITIVE
NOX Principal Investigator Discusses LuPIN-1 Study
14/01/19PRICE SENSITIVE
NOX Change of Director's Interest Notice - GK
21/12/18
NOX Section 708 Certificate
21/12/18
NOX Appendix 3B
21/12/18
NOX NOX Receives $3.26M Federal Govt R&D Rebate
20/12/18PRICE SENSITIVE
NOX DARRT-1 study advancing on basis of positive clinical data
11/12/18PRICE SENSITIVE
NOX NOX announces Positive Data from CEP-1 Study of Veyonda
29/11/18PRICE SENSITIVE
NOX Initial Director's Interest Notice
21/11/18
NOX Results of Meeting
21/11/18
NOX Appointment of Mr John Moore as Non-Executive Director
21/11/18
NOX NOX 2018 AGM Presentations
21/11/18
NOX NOX 2018 AGM Information
20/11/18
NOX NOX to Present Clinical Data at COSA Annual Meeting
13/11/18PRICE SENSITIVE
NOX Corporate Presentation
08/11/18
NOX Appendix 4C - quarterly
26/10/18PRICE SENSITIVE
NOX NOX makes key executive appointment
22/10/18
NOX Notice of Annual General Meeting & Proxy Form
05/10/18
NOX Noxopharm Releases Report on Key Progress of Subsidiary
04/10/18
NOX Section 708 Certificate
02/10/18
NOX Appendix 3B
02/10/18
NOX Change of Director's Interest Notice - PM
28/09/18
NOX Section 708 Certificate
28/09/18
NOX Appendix 3B
28/09/18
NOX Change of Registry Address: Automic P/L - Sydney Office
28/09/18
NOX Annual Report to shareholders
27/09/18
NOX Corporate Governance Statement - Appendix 4G
27/09/18
NOX Corporate Governance Statement - 2018
27/09/18
NOX NOX Subsidiary Announces Important Drug Discovery
24/09/18PRICE SENSITIVE
NOX NOX to support expanded LuPIN study
05/09/18PRICE SENSITIVE
NOX Appendix 4E and Audited Financial Statements
30/08/18PRICE SENSITIVE
NOX Nyrada-Key progress with cholesterol-lowering drug candidate
27/08/18PRICE SENSITIVE
NOX VEYONDA - Registered Trade Mark for NOX66
20/08/18PRICE SENSITIVE
NOX NOX Corporate Presentation FNN-Shaw&Partners Investor Event
14/08/18
NOX Change of Director's Interest Notice - GK
09/08/18
NOX Change of Director's Interest Notice - PM
09/08/18
NOX Change of Director's Interest Notice - ID
09/08/18
NOX Appendix 3B
09/08/18
NOX Interim NOX66 Radiotherapy Clinical Data
08/08/18
NOX Appendix 4C - quarterly
30/07/18PRICE SENSITIVE
NOX Securities to be released from Escrow
10/07/18 download Created with Sketch. 77.33KB
NOX Release of DARRT-1 Preliminary Safety Data
09/07/18PRICE SENSITIVE download Created with Sketch. 239.09KB
NOX Pre-Clinical data confirms Radio-Enhancing potential
05/07/18PRICE SENSITIVE download Created with Sketch. 169.52KB
NOX Noxopharm releases Nyrada Corporate Presentation
07/06/18 download Created with Sketch. 1.54MB
NOX Noxopharm Corporate Presentation for Public Briefing
07/06/18 download Created with Sketch. 13.14MB
NOX End-of-Study Clinical Data shows benefit of NOX66
05/06/18PRICE SENSITIVE download Created with Sketch. 264.42KB
NOX Noxopharm 2018 Mid-Year Investor Briefings
31/05/18 download Created with Sketch. 150.63KB
NOX Section 708 Certificate
28/05/18 download Created with Sketch. 233.72KB
NOX Appendix 3B
28/05/18 download Created with Sketch. 564.14KB
NOX NOX to present at American Society of Clinical Oncology
22/05/18PRICE SENSITIVE download Created with Sketch. 257.98KB
NOX KZA: Progress Report
21/05/18
NOX Change in substantial holding
21/05/18
NOX Securities to be released from Voluntary Escrow
21/05/18
NOX Section 708 Certificate
21/05/18
NOX Appendix 3B
21/05/18
NOX Noxopharm 2018 Mid-Year Investor Briefings
18/05/18
NOX Results of Meeting
15/05/18
NOX NOX CEO interview updates the company's current R&D program
07/05/18
NOX NOX CEO interview on near complete NOX66 chemotherapy trial
03/05/18PRICE SENSITIVE
NOX NOX CEO interview on Radiotherapy Clinical Programs
27/04/18PRICE SENSITIVE
NOX Appendix 4C - quarterly
27/04/18PRICE SENSITIVE
NOX St Vincent's Hospital study passes first milestone
17/04/18PRICE SENSITIVE
NOX Notice of Extraordinary General Meeting / Proxy Form
09/04/18
NOX Change in substantial holding
06/04/18
NOX Change in substantial holding
06/04/18
NOX DARRT-1 Clinical Study commences
05/04/18PRICE SENSITIVE
NOX NOX Mid-Year Briefings
05/04/18
NOX Section 708 Certificate
29/03/18
NOX Appendix 3B
29/03/18
NOX NOX raises $10.8 M to advance clinical program
23/03/18PRICE SENSITIVE
NOX Trading Halt
21/03/18PRICE SENSITIVE
NOX Evidence of Abscopal Responses in Patients
21/03/18PRICE SENSITIVE
NOX Corporate Presentation - Post Interim Clinical Data Release
12/03/18
NOX FNN Interview with Noxopharm CEO
09/03/18
NOX NOX Reports NOX66 Clinical Data
06/03/18PRICE SENSITIVE
NOX Trading Halt
05/03/18PRICE SENSITIVE
NOX Update accompanying Half Year Report
23/02/18
NOX Appendix 4D and Half Year Accounts
23/02/18PRICE SENSITIVE
NOX NOX closes $4m capital raising for US subsidiary Nyrada Inc
16/02/18PRICE SENSITIVE
NOX Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
NOX Section 708 Certificate
25/01/18
NOX Appendix 3B
25/01/18
NOX KZA: Receipt of securities in Noxopharm Limited (NOX)
22/01/18
NOX Section 708 Certificate
18/01/18
NOX Appendix 3B
18/01/18
NOX NOX receives FY17 R&D Tax Rebate
17/01/18PRICE SENSITIVE
NOX Kazia Therapeutics Ltd and Noxopharm Ltd
27/12/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.0¢ 		Change
-0.005(4.76%) 		Mkt cap ! $29.22M
Open High Low Value Volume
11.5¢ 11.5¢ 10.0¢ $6.181K 58.01K

Buyers (Bids)

No. Vol. Price($)
4 42445 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 14000 1
View Market Depth
Last trade - 16.10pm 26/11/2024 (20 minute delay) ?
Last
10.0¢ 		  Change
-0.005 ( 9.09 %)
Open High Low Volume
10.0¢ 10.0¢ 10.0¢ 2527
Last updated 15.59pm 26/11/2024 ?
NOX (ASX) Chart

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
'Taking money from the market': Garbage giant cleans up as this week's Hot Stock tip Wealth Within chief analyst Dale Gillham and senior analyst Fil Tortevski have tipped $4.68 billion garbage giant Cleanaway Waste Management Limited (ASX:CWY) as their Hotcopper Hot Stock tip of the week @ especially because it seems to be slowly building towards a euphoric run akin to its mid 20...
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.